BWA
LXRX icon

Basecamp Wealth Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Basecamp Wealth Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66K Hold
691
– – ﹤0.01% 1411
2026
Q1 		$1.08K Hold
691
– – ﹤0.01% 1544
2025
Q4 		$795 Buy
+691
New +$949 ﹤0.01% 1539

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Basecamp Wealth Advisors's LXRX Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 691 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Basecamp Wealth Advisors first reported a position in LXRX in Q4 2025 and has held it in 3 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Basecamp Wealth Advisors held 691 shares of Lexicon Pharmaceuticals worth $1.66K as of Q2 2026.
  • Basecamp Wealth Advisors left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1411 holding.
  • Basecamp Wealth Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.